RELMADA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.53 USD | -7.11% |
|
-4.08% | -14.73% |
| May. 08 | Transcript : Relmada Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 | |
| May. 08 | Relmada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Presentation Operator MessageOperator (Operator)Good afternoon. My name is Kathy, and I'll be ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Companyâs lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.
Calendar
2024-05-24
- Annual General Meeting
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
3.53
USD
Average target price
13.5
USD
Spread / Average Target
+282.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.73% | 107M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- RLMD Stock
- News Relmada Therapeutics, Inc.
- Transcript : Relmada Therapeutics, Inc., Q3 2022 Earnings Call, Nov 10, 2022
